The meta-analysis found that GLP-1 receptor agonists produced greater weight loss in women than in men, but no significant heterogeneity of treatment effect by age, race, ethnicity, baseline BMI, or baseline HbA1c was detected across the randomized trials analyzed. For comparative efficacy, the broa...
ViewThe CMBCD staging model is presented as an early and sustainable preventive care plan for cardiometabolic-based chronic disease, aimed at targeting early mechanistic events to reduce risk for coronary heart disease, heart failure, and atrial fibrillation. The review says the practical emphasis is on...
ViewQ1. How do the attached sources describe ATT&CK at a high level? - A globally-accessible knowledge base of adversary tactics and techniques based on real-world observations - A catalog of only malware hashes and file signatures - A framework that lists only vulnerability severity scores - A patch-ma...
ViewThe supplied source set is overwhelmingly cardiometabolic: two JACC review pieces on cardiometabolic-based chronic disease, one systematic review and meta-analysis of GLP-1 receptor agonists for weight loss, and one systematic review of medication adherence thresholds. I do not see oncology, infecti...
ViewIf your ICS can be reached from the Internet, it is already too exposed. CISA’s recurring advice is to reduce reachability first, then layer in segmentation, firewalls, and controlled remote access[[cite:1]][[cite:2]]. Step 1: review the advisory’s affected software or firmware versions and confirm ...
ViewShould KEV outrank CVSS in vulnerability triage? **Yes.** The attached CISA and EPSS sources support an exploitation-led triage model: confirmed exploitation in CISA KEV should outrank severity-only CVSS scoring, while EPSS is used as a probability signal when active exploitation is not already evid...
ViewThe strongest publishable clusters are: active exploitation as the remediation trigger in KEV, ICS exposure and segmentation risk, and access-control abuse in web apps that ATT&CK-style adversary mapping helps defenders normalize and detect. Across the sources, the repeated detection idea is to trea...
ViewWhat these sources emphasize The common thread is prioritizing vulnerabilities based on real-world exploitation, then using that signal to drive patching, detection, and containment. CISA says the KEV catalog is for vulnerabilities with a CVE ID, reliable evidence of active exploitation in the wild,...
ViewQ1. What do investors in an RSE Collection offering actually purchase? - The collectible automobile itself - Membership interests in a specific series tied to one underlying asset - A share of RSE Collection, LLC as a whole - A guaranteed claim on the manager's entire inventory Answer: Membership in...
ViewThe strongest cross-source finding is consistent: these records emphasize vulnerabilities that are actively exploited or likely to be exploited, with remediation prioritized through CISA's KEV catalog, while EPSS is used as a probability signal when exploitation evidence is not already known. Major ...
ViewWix warns it may struggle to attract users, keep premium subscribers, and grow revenue per subscription. Wix treats AI as a business opportunity and a risk, citing legal, regulatory, reputational, and output-quality exposure. Wix says payment processing exposes it to billing failures, chargebacks, f...
ViewThree very different systems point to the same lesson. In the software quality patent, quality is assessed by tracing requirements through a Scenario Branch Diagram, then a scenario diagram, then a method flow diagram, with metrics built around scenario logic, business rules, state transitions, and ...
ViewVinci Compass: how AUM turns into distributable earnings The filings describe a layered model in which assets under management feed recurring fees first, then more variable performance and investment economics, and finally a dividend-oriented distributable earnings measure.[[cite:1]][[cite:2]][[cite...
ViewMesoblast says it had cash and cash equivalents of $60.4 million at June 30, 2022, and that it believed those reserves were sufficient to meet the next 12 months of expenditure, including the BLA approval process for remestemcel-L in pediatric SR-aGVHD. The company also says it raised $45.0 million ...
ViewCompass Pathways says it has incurred significant losses since inception, expects to keep losing money for the foreseeable future, and may never achieve or maintain profitability. The company also says it will need substantial additional funding to continue operations and advance COMP360 development...
View